Article info
PDFResearch Article
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
- ↵a sbhatia{at}uw.edu
- ↵b brendan.curti{at}providence.org
- ↵c marc.s.ernstoff{at}hitchcock.org
- ↵d mgordon{at}azpoh.com
- ↵e heathe{at}karmanos.org
- ↵f wmiller{at}jgh.mcgill.ca
- ↵g igor.puzanov{at}vanderbilt.edu
- ↵h diquinn{at}usc.edu
- ↵i Thomas.Flaig{at}ucdenver.edu
- ↵j pvanveldhuizen{at}kumc.edu
- ↵k Kelly_blake{at}live.com
- ↵l seattlefreeman{at}gmail.com
- ↵m Rachel.Bittner{at}bms.com
- ↵n naomi.hunder{at}gmail.com
- ↵o sonia.souza{at}gmail.com
- ↵p jat{at}uw.edu
Citation
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Publication history
- Received October 25, 2013
- Accepted January 20, 2014
- First published January 27, 2014.
Online issue publication
February 09, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.